Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

OTIS Vedolizumab Pregnancy Exposure Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02678052
Recruitment Status : Recruiting
First Posted : February 9, 2016
Last Update Posted : September 10, 2020
Sponsor:
Information provided by (Responsible Party):
Takeda

Brief Summary:
The purpose of this study is to assess the prevalence of major structural birth defects in infants of female participants with ulcerative colitis (UC) or Crohn's disease (CD) exposed to vedolizumab during pregnancy, compared to participants with UC or CD exposed to other biologic agents.

Condition or disease Intervention/treatment
Colitis, Ulcerative Crohn's Disease Drug: Vedolizumab Biological: Other Biological Agent

Detailed Description:

The drug being observed in this study is called Vedolizumab. Vedolizumab is approved for the treatment of adult participants with moderately to severely active UC and CD who achieved an inadequate response, had a loss of response, or were intolerant to conventional and/or biologic treatments. This study will look at any possible association between vedolizumab and pregnancy outcome, including the health of the mother, fetus, and infant in the female with planned and unplanned pregnancies and who are at least 1 dose exposed at any time from last menstrual period (LMP) during pregnancy to vedolizumab (Entyvio) or other biological agents for UC or CD.

The study will enroll approximately 200 pregnant female participants drawn from 3 sources: OTIS Network, pregnant women who spontaneously contact the study research center or the sponsor or who are referred by their health care practitioners (HCP) in North America and women in North America who become pregnant while participating in other Entyvio clinical studies being undertaken by the sponsor. Participants will be assigned to one of the two cohorts:

  • No chronic disease prospective cohort
  • UC/CD prospective cohort All participants will be observed throughout the study. All participants will be asked to record all medications (including dose, frequency, and route), any additional exposures or events as the pregnancy progresses in a pregnancy diary.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is 6 years. Cohort enrollment will be done before 20 weeks of gestation period and intake interviews would be scheduled telephonically. Schedule of intake interviews of participants will depends upon the duration of LMP prior to enrollment of participants in study. Outcome interview would be conducted within 0 to 6 weeks after delivery, dysmorphological examination of live infants would be conducted within 0 to 12 months after delivery and pediatric medical record review and questionnaire would be held 1 year after delivery.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Organization of Teratology Information Specialists (OTIS) Vedolizumab Pregnancy Exposure Registry
Actual Study Start Date : December 1, 2015
Estimated Primary Completion Date : November 30, 2022
Estimated Study Completion Date : August 31, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Vedolizumab

Group/Cohort Intervention/treatment
Cohort 1: No Chronic Disease
Pregnant women without a current diagnosis of any chronic disease with no exposure to any biological agent and at any time from first day of last menstrual period (LMP) will be observed for up to 1 year.
Cohort 2: UC/CD Prospective Cohort
Pregnant women with current diagnosis of UC or CD with exposure to Entyvio or other biologic agents during pregnancy at any dose, and at any time from first day of LMP will be observed for up to 1 year.
Drug: Vedolizumab
Vedolizumab exposure
Other Name: Entyvio

Biological: Other Biological Agent
Other Biological Agent exposure




Primary Outcome Measures :
  1. Major Structural Birth Defects Identified in Infants After Birth [ Time Frame: Baseline up to 1 year ]
    A major structural defect is defined as a defect that has either cosmetic or functional significance to the child (eg, a cleft lip), as defined by the Centers for Disease Control and Prevention (CDC). These defects in aggregate typically occur in less than (<) 4% of the general population. Over 100 specific structural defects are considered to be major. Baseline will be considered as the time of birth of child.


Secondary Outcome Measures :
  1. Minor Structural Birth Defects Identified in Infants After Birth [ Time Frame: Baseline up to 1 year ]
    A minor structural defect is defined as a defect that has neither cosmetic nor functional significance to the child (for example: complete 2,3 syndactyly of the toes) and will be identified using a study-related checklist incorporated into the study dysmorphology examination of live born infants. Baseline will be considered at the time of birth of child.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 44 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Pregnant woman with or without UC or CD with exposure to Entyvio or any other biological agent (only for women with UC or CD) during pregnancy will be observed in this study.
Criteria

Inclusion Criteria:

For the UC/CD Prospective Cohort:

  1. Is a currently pregnant woman with UC or CD,
  2. Has exposure to Entyvio or other biologic agents at any dose, and at any time from first day of LMP,
  3. Has enrolled no later than 19 completed weeks after LMP.
  4. Agrees to the conditions and requirements of the study including the interview schedule, release of medical records, and the physical examination of live born infants.

    For the 'no chronic disease' Prospective Cohort:

  5. Is a currently pregnant woman with no chronic disease.
  6. Has no exposure to any biological agent and at any time from first day of LMP,
  7. Has enrolled no later than 19 completed weeks after LMP.
  8. Agrees to the conditions and requirements of the study including the interview schedule, release of medical records, and the physical examination of live born infants.

Exclusion Criteria:

For the UC/CD Prospective Cohort:

  1. Is greater than (>) 19 completed weeks gestation prior to enrollment,
  2. Has first contact with OTIS after prenatal diagnosis of any major structural defect,
  3. Has enrolled in this registry with a previous pregnancy,
  4. Has had an exposure to the known or suspected human teratogens: Chlorambucil. Cyclophosphamide, Mycophenylate mofetil.

    For the 'no chronic disease' Prospective Cohort:

  5. Is >19 completed weeks gestation prior to enrollment,
  6. Has first contact with OTIS after prenatal diagnosis of any major structural defect,
  7. Has enrolled in this registry with a previous pregnancy,
  8. Has had an exposure to the known or suspected human teratogens: Chlorambucil, Cyclophosphamide, Mycophenylate mofetil.

Note: women exposed to Entyvio during pregnancy but not meeting the above criteria can enroll into the Entyvio pregnancy exposure case series component of this registry.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02678052


Contacts
Layout table for location contacts
Contact: Takeda Study Registration Call Center +1-877-825-3327 medinfoUS@takeda.com

Locations
Layout table for location information
United States, California
Recruiting
San Diego, California, United States
Canada
Recruiting
Multiple Locations, Canada
Sponsors and Collaborators
Takeda
Investigators
Layout table for investigator information
Study Director: Medical Director Takeda
Layout table for additonal information
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT02678052    
Other Study ID Numbers: Vedolizumab-5001
First Posted: February 9, 2016    Key Record Dates
Last Update Posted: September 10, 2020
Last Verified: September 2020
Keywords provided by Takeda:
Drug therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Colitis, Ulcerative
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Colitis
Colonic Diseases
Vedolizumab
Gastrointestinal Agents